



OxySure (OXYS) and Z-Medica Sign Distribution Agreement

Frisco, Texas, June 15, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other innovative medical device solutions, announced today the signing of a distribution agreement with Z-Medica, LLC, a leading developer of hemostatic devices like QuikClot Combat Gauze®. “We are pleased to add QuikClot bleeding control devices to our current emergency medical and resuscitation product offerings,” said Clark Hood, Vice President of Resuscitation Sales for OxySure. “We believe this is another significant milestone in our mission to become a leading supplier of critical life-saving emergency response products in the first responder, school and public access markets. Adding QuikClot to our current Model 615 emergency oxygen system and automated external defibrillator (AED) offerings is a natural fit for our organization,” he added.

“The product lines of Z-Medica and OxySure run paralleled in that both companies create medical devices that can save lives when minutes count,” said Stephen J. Fanning, President and CEO of Z-Medica. “We look forward to partnering with OxySure and expanding our distribution channels to fulfill unmet public safety needs.”

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com

About Z-Medica, LLC

Z-Medica, LLC is a medical device company founded in 2002 developing fast acting, easy to use, hemostatic products that stop bleeding wherever it occurs, making it possible to save lives and improve patient outcomes. Based on tests conducted by the Naval Medical Research Center and the U.S. Army Institute for Surgical Research, the Committee on Tactical Combat Casualty Care (CoTCCC) chose QuikClot Combat Gauze® as the hemostatic dressing of choice on the

battlefield for compressible hemorrhage not amenable to tourniquet use or as an adjunct to tourniquet removal if evacuation time is anticipated to be longer than 2 hours.

QuikClot® products are developed and manufactured in the United States. Z-Medica, LLC is a privately-held company based in Wallingford, CT. For more information, visit

<http://www.quikclot.com>

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

Investor Contacts:

Renmark Financial Communications, Inc.

Bettina Filippone: bfilippone@renmarkfinancial.com

Richard Dupuy: rdupuy@renmarkfinancial.com

Tel.: (416) 644-2020 or (514) 939-3989

www.renmarkfinancial.com/

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107

www.redchip.com/

For Z-Medica:

Dave Schemelia, EVCGroup

dave@evcgroup.com

(646) 201-5431 or (609) 468-9325